Organogenesis (NASDAQ:ORGO) Receives “Buy” Rating from BTIG Research

BTIG Research reissued their buy rating on shares of Organogenesis (NASDAQ:ORGO) in a report released on Thursday morning,Benzinga reports. BTIG Research currently has a $8.00 price objective on the stock.

Several other brokerages have also weighed in on ORGO. Weiss Ratings raised Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a research report on Friday, February 27th. Wall Street Zen raised Organogenesis from a “hold” rating to a “buy” rating in a report on Sunday, March 8th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Organogenesis Stock Performance

Shares of ORGO stock opened at $2.42 on Thursday. The company has a market cap of $311.31 million, a P/E ratio of 30.25 and a beta of 1.43. The firm has a fifty day moving average price of $3.39 and a 200 day moving average price of $4.29. The company has a current ratio of 3.62, a quick ratio of 3.32 and a debt-to-equity ratio of 0.04. Organogenesis has a 12 month low of $2.31 and a 12 month high of $7.08.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.10. The company had revenue of $225.61 million for the quarter, compared to analysts’ expectations of $172.68 million. Organogenesis had a return on equity of 21.41% and a net margin of 5.32%. Sell-side analysts predict that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Insider Activity at Organogenesis

In other news, Director Michael Joseph Driscoll bought 10,000 shares of Organogenesis stock in a transaction dated Monday, March 9th. The stock was acquired at an average cost of $2.67 per share, with a total value of $26,700.00. Following the acquisition, the director owned 225,707 shares of the company’s stock, valued at approximately $602,637.69. This trade represents a 4.64% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 33.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. State of Alaska Department of Revenue acquired a new stake in shares of Organogenesis in the third quarter valued at approximately $25,000. Quarry LP purchased a new position in shares of Organogenesis during the third quarter worth approximately $25,000. Flagship Harbor Advisors LLC acquired a new position in shares of Organogenesis in the 4th quarter valued at $34,000. Federated Hermes Inc. increased its holdings in shares of Organogenesis by 52.8% in the 4th quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock valued at $44,000 after acquiring an additional 2,953 shares during the period. Finally, Walleye Capital LLC purchased a new stake in Organogenesis in the 2nd quarter valued at $45,000. Institutional investors and hedge funds own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.